-
Posted by
Two Blokes Jun 26 -
Filed in
Stock
-
2 views
Changes Based on Additional Pharmacokinetics Data TORRANCE, Calif. , June 26, 2025 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today that it has received Food and Drug Administration (FDA) approval for changes to the labelling of Endari\u00ae to reflect additional prescribing information derived from post-marketing pharmacokinetic study data submitted by Emmaus.
